Profile data is unavailable for this security.
About the company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
- Revenue in USD (TTM)0.00
- Net income in USD-10.10m
- Incorporated2008
- Employees5.00
- LocationTenax Therapeutics Inc101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL 27517United StatesUSA
- Phone+1 (919) 855-2100
- Fax+1 (302) 655-5049
- Websitehttp://www.tenaxthera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 5.58m | 22.00 | -- | 0.9582 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
TFF Pharmaceuticals Inc | 885.71k | -19.93m | 5.61m | 19.00 | -- | 0.8596 | -- | 6.33 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
HST Global Inc | 0.00 | -141.11k | 5.72m | 1.00 | -- | -- | -- | -- | -0.0269 | -0.0269 | 0.00 | -0.1193 | 0.00 | -- | -- | -- | -29,397.92 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -24.24 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Intelligent Bio Solutions Inc | 2.83m | -10.03m | 5.74m | 17.00 | -- | 0.4816 | -- | 2.03 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
Transcode Therapeutics Inc | 0.00 | -17.06m | 5.75m | 10.00 | -- | 1.10 | -- | -- | -206.36 | -206.36 | 0.00 | 0.7893 | 0.00 | -- | -- | 0.00 | -264.82 | -133.14 | -721.90 | -181.26 | -- | -- | -- | -- | -- | -148.05 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
Xenetic Biosciences Inc | 2.44m | -4.47m | 5.77m | 4.00 | -- | 0.6648 | -- | 2.36 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
CeCors Inc | -100.00bn | -100.00bn | 5.81m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Burzynski Research Institute Inc | 0.00 | -1.34m | 5.83m | 2.00 | -- | -- | -- | -- | -0.0102 | -0.0102 | 0.00 | -0.0002 | 0.00 | -- | -- | -- | -62,992.45 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
NuCana PLC (ADR) | 0.00 | -33.94m | 5.85m | 25.00 | -- | 0.4868 | -- | -- | -303.31 | -303.31 | 0.00 | 5.68 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
Ainos Inc | 93.68k | -14.56m | 5.91m | 46.00 | -- | 0.2547 | -- | 63.06 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
Cyclerion Therapeutics Inc | 0.00 | -10.95m | 6.11m | 1.00 | -- | 0.568 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -10.10m | 6.23m | 5.00 | -- | 0.501 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
Kazia Therapeutics Ltd (ADR) | 15.18k | -13.77m | 6.29m | 12.00 | -- | 0.5936 | -- | 414.27 | -0.835 | -0.835 | 0.0008 | 0.3555 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Enzolytics Inc | 0.00 | -119.19k | 6.38m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
ENDRA Life Sciences Inc | 0.00 | -9.89m | 6.39m | 21.00 | -- | 0.2686 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
Virios Therapeutics Inc | 0.00 | -5.07m | 6.66m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Heights Capital Management, Inc.as of 11 Apr 2024 | 204.03k | 10.42% |
S.H.N. Financial Investments Ltd.as of 11 Apr 2024 | 107.00k | 5.46% |
Qube Research & Technologies Ltd.as of 31 Mar 2024 | 4.41k | 0.23% |
UBS Securities LLCas of 31 Mar 2024 | 1.38k | 0.07% |
Tower Research Capital LLCas of 31 Mar 2024 | 537.00 | 0.03% |
CIBC Private Wealth Advisors, Inc.as of 31 Mar 2024 | 343.00 | 0.02% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 300.00 | 0.02% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 260.00 | 0.01% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 2.00 | 0.00% |
Allworth Financial LPas of 31 Mar 2024 | 1.00 | 0.00% |